This CME Activity has expired and is no longer available for credit.
Treatment-Resistant, Hormone-Positive Breast Cancer: Next Steps & New Paradigms
Time to Complete
October 5, 2012
October 18, 2014
Updated Expiration Information
This CME-certified activity has been granted an extension for twelve months as the content was deemed relevant and current according to the standards set forth by the Society for Translational Oncology (STO) and Massachusetts General Hospital.
Release date: October 5, 2012 Review: October 18, 2013 Expiration date: October 18, 2014
1.00 / AMA PRA Category 1 Credit(s)TM
Jointly sponsored by the Society for Translational Oncology and Massachusetts General Hospital.
Supported through an educational grant from Genentech, Novartis, and Genomic Health
Estrogen- and/or progesterone-positive breast cancer is highly responsive to endocrine therapy. However, such cancers nearly always develop endocrine resistance. The most appropriate management options for women with endocrine-resistant breast cancer are unclear, so it’s critical for clinicians to remain informed about the most clinically relevant outcomes of trials presented/published in the past 18 months, in order to most effectively manage treatment-resistant MBC.
Community oncologists, surgical oncologists, radiation oncologists, pathologists, oncology nurses, and other health care professionals involved in the care and treatment of women with breast cancer.
At the end of this online enduring material, participants should be able to:
Identify molecular pathways that contribute to endocrine and trastuzumab resistance and discuss their implications for treatment.
Discuss the outcomes of the most recent clinical trials related to the management of women with treatment-resistant breast cancer, including those with triple-negative breast cancer.
In accord with the disclosure policy of The Society for Translational Oncology (STO) as well as guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.
The speaker of this activity, Michaela J. Higgins, Mb.Bch, has indicated that neither she nor her spouse/partner have a relevant financial relationship to disclose.
Planning Staff Disclosure
The following planner of this activity has indicated that she and/or her spouse/partner do have a relevant financial relationship to disclose: Beverly Moy, MD Consulting: GlaxoSmithKline, Pfizer
The Internet was selected as the medium for this activity to accommodate the learning preferences of a significant portion of the target audience.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Society for Translational Oncology (STO) and Massachusetts General Hospital. The Society for Translational Oncology (STO) is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Society for Translational Oncology designates this enduring material for a maximum of one (1) AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Method of Participation: To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.